Xtandi is indicated for: the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see Pharmacology: Pharmacodynamics under Actions); the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see Pharmacology: Pharmacodynamics under Actions); the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see Pharmacology: Pharmacodynamics under Actions); the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
Sign Out
